Prestige BioPharma focuses on discovery and development of innovative new biologics as well as biosimilars.
PBP's first biosimilar HD201, Trastuzumab, successfully completed Phase I clinical trial in EU in 2014 and currently under Phase III development.
PBP thrives to become one of the top biopharmaceuticals specializing in discovery of new biologics and next series of biosimilars.
2 Science Park Drive #04-13/14
Ascent Tower B
Singapore Science Park
Phone: +65 6924 6535
Fax: +65 6924 2053
Prestige BioPharma Pte Ltd
Creating Differences & Value for Human Health
News & Resources
PBP's R&D facilities located in the Biomedical Park of Singapore boast well-equipped multidisciplinary research infrastructure, supporting pharmaceutical R&D activities from discovery to nonclinical and clinical development. Read More